SAN2265

SAN2265 is a small molecule drug candidate developed by Saniona in partnership with Boehringer Ingelheim. It functions as a modulator of the Kv7 (KCNQ) family of potassium channels and is currently in Phase 1 clinical development. The Kv7 channel family plays a critical role in regulating neuronal excitability; by enhancing the activity of these channels, SAN2265 aims to stabilize overactive neurons and restore normal signaling. While the specific target indication for this partnered program has not been explicitly detailed in the primary pipeline summary, the mechanism is highly relevant for central nervous system (CNS) disorders such as epilepsy and neuropathic pain. The drug was developed using Saniona's proprietary ion channel platform, which focuses on identifying subtype-selective modulators to improve therapeutic outcomes in neurological and psychiatric conditions.